Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a single infusion of VX-880 allowed a dozen diabetes patients to begin producing their own insulin. It worked so well that nearly everyone treated has reduced their reliance on regular insulin injections.
In response to good news from the VX-880 program, Wells Fargo analyst Mohit Bansal raised his price target to $555 and maintained an overweight rating. The new target implies a gain of about 19% from recent prices.
Is Vertex Pharmaceuticals a good investment right now? Let's weigh its strengths against some of its challenges to find out.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
453,20 €
-3,26 %
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 450 €, das unter 453.2 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -0.71%.
